argenx (ARGX) Resumen de Acciones
argenx SE, empresa biofarmacéutica en fase comercial, desarrolla diversas terapias para el tratamiento de enfermedades autoinmunes en Estados Unidos, Japón, China, Países Bajos y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 5/6 |
| Rendimiento pasado | 3/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
ARGX Community Fair Values
Create NarrativeSee what 71 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
€686.43
FV
0.6% sobrevalorado descuento intrínseco15.00%
Revenue growth p.a.
7
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Competidores de argenx SE
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | €690.40 |
| Máximo en las últimas 52 semanas | €810.00 |
| Mínimo de 52 semanas | €456.60 |
| Beta | -0.057 |
| Cambio en 1 mes | -2.43% |
| Variación en 3 meses | -3.79% |
| Cambio de 1 año | 32.31% |
| Variación en 3 años | 82.98% |
| Variación en 5 años | 207.25% |
| Variación desde la OPV | 8,639.24% |
Noticias y actualizaciones recientes
Actualización de narrativa • May 14
ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power
Analysts nudged their blended price target for argenx higher by about €2 to roughly €845, citing a slightly higher fair value estimate, modestly adjusted growth and discount rate assumptions, and support from recent research highlighting Vyvgart momentum and an expanded late stage pipeline. Analyst Commentary Recent research shows a split between analysts trimming targets on fine tuned assumptions and others lifting or reaffirming higher fair value estimates.
Actualización de narrativa • Apr 29
ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential
Analysts have nudged their argenx price targets slightly lower in recent weeks, trimming individual fair values by €30 to €92. They continue to cite ongoing Vyvgart momentum, a broader late stage pipeline and a less demanding valuation as key supports for the updated outlook.Recent updates
Actualización de narrativa • May 14
ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power
Analysts nudged their blended price target for argenx higher by about €2 to roughly €845, citing a slightly higher fair value estimate, modestly adjusted growth and discount rate assumptions, and support from recent research highlighting Vyvgart momentum and an expanded late stage pipeline. Analyst Commentary Recent research shows a split between analysts trimming targets on fine tuned assumptions and others lifting or reaffirming higher fair value estimates.Actualización de narrativa • Apr 29
ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential
Analysts have nudged their argenx price targets slightly lower in recent weeks, trimming individual fair values by €30 to €92. They continue to cite ongoing Vyvgart momentum, a broader late stage pipeline and a less demanding valuation as key supports for the updated outlook.Actualización de narrativa • Apr 15
ARGX: Late Stage Neuromuscular Readouts Will Support Future Earnings Power
Analysts have made a modest upward tweak to the fair value estimate for argenx to €842.55, reflecting updated assumptions for Vyvgart momentum, slightly higher revenue growth expectations around 26.7%, a somewhat lower profit margin near 34.7%, and a higher future P/E of about 25.5x following recent price target revisions and ongoing support from research firms despite generally lower headline targets. Analyst Commentary Recent Street research on argenx reflects generally constructive views on Vyvgart execution and the broader pipeline, with some caution around spending plans and the current valuation.Actualización de narrativa • Apr 01
ARGX: Graves And gMG Expansion Will Drive Future Repricing Potential
Analysts have nudged the blended price target for argenx slightly higher to about €991. This reflects updated assumptions that pair more moderate revenue growth with a higher profit margin outlook and a somewhat richer future P/E, supported by recent research citing steady Vyvgart momentum, consistent profitability and a deep late stage pipeline.Actualización de narrativa • Mar 17
ARGX: Late Stage Neuromuscular Pipeline Readouts Will Drive Future Upside
Argenx's updated analyst price target reflects a modest recalibration, with fair value edging from about €845 to €839 as analysts factor in ongoing Vyvgart momentum, a slightly lower future P/E assumption and continued profitability. Analyst Commentary Recent Street research on argenx clusters around two themes: execution on Vyvgart and how much of that outlook is already reflected in the share price.Actualización de narrativa • Mar 03
ARGX: Expanded Neuromuscular Indications Will Drive Long Term Upside Potential
The analyst fair value estimate for argenx edges up from €825.51 to €845.07, as analysts trim long term growth and margin assumptions while still pointing to Vyvgart uptake, late stage pipeline breadth, and ongoing price targets mostly above the current level as key supports for the updated price target range. Analyst Commentary Recent Street research shows a mixed but generally constructive tone around argenx, with price targets adjusted both up and down while ratings largely stay positive.Actualización de narrativa • Feb 17
ARGX: Vyvgart Expansion Into Seronegative gMG Will Support Long Term Upside
Narrative Update Analysts have raised their average price target on argenx by a few euros to €825.51. This reflects updated models that incorporate slightly higher revenue growth assumptions, a modestly higher future P/E multiple and recent target increases from firms citing steady long term confidence in the story.
Actualización de narrativa • Feb 03
ARGX: Future Sector Correlation Risk May Undermine Elevated Biotech Thesis
Analysts have lifted their fair value estimate for argenx from US$528.05 to US$614.80, citing updated models that incorporate revised revenue growth, profit margin and future P/E assumptions, in line with a series of recent price target increases from major brokerage firms. Analyst Commentary Recent Street research on argenx has featured a series of higher price targets in both U.S. dollars and euros, reflecting updated models rather than wholesale shifts in underlying views.Actualización de narrativa • Jan 20
ARGX: Graves Disease And gMG Franchise Will Drive Future Repricing
Analysts have raised their fair value estimate for argenx from about $885 to roughly $990.88, citing higher modeled revenue growth assumptions, updated P/E expectations, and a series of price target increases across the Street. Analysts continue to view the company constructively, even as some lists are being rebalanced.Actualización de narrativa • Jan 06
ARGX: Vyvgart Franchise Expansion Will Drive Upside Despite Pipeline Setbacks
Analysts have lifted their fair value estimate for argenx from $797.32 to $820.09. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E after recent research that highlighted solid Q3 execution, optimism around Vyvgart's opportunity and some recalibration of upside potential.Actualización de narrativa • Dec 15
ARGX: Future Pipeline Readouts Will Balance Post Rally Expectations And Execution Risks
Analysts have nudged their average price target on argenx modestly higher by about $30 per share. This reflects stronger assumed revenue growth and higher future valuation multiples, even as they temper margin expectations in light of a more selective, probability-weighted view of the Vyvgart and empasiprubart pipelines.Actualización de narrativa • Nov 30
ARGX: Share Momentum Will Balance Pipeline Progress Against Post-Rally Expectations
Argenx's analyst price target has been modestly revised downward by approximately $4 to $766. Analysts are balancing optimism on new clinical data and pipeline expansion with tempered expectations following the recent stock rally.Actualización de narrativa • Nov 16
ARGX: Shares Will Weigh Expanding Indications Against Cooling Market Enthusiasm
Analysts have raised their price target for argenx by over $20 to approximately $770. They cite strong third-quarter performance, broadening growth drivers across Vyvgart indications, and confidence in the company’s expanding pipeline and commercial prospects.Actualización de narrativa • Nov 02
ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook
Argenx's analyst price target has increased by over $24 to approximately $749. Analysts cite solid quarterly results, pipeline progress, and expanded commercial opportunities as key drivers for the upward revision.Actualización de narrativa • Sep 25
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
argenx’s consensus price target has been revised upward to €724.38 as analysts raise growth forecasts following strong Phase 3 Vyvgart data and expanding market opportunity, while improved revenue projections and robust pipeline momentum continue to offset valuation concerns. Analyst Commentary Bullish analysts are raising price targets on Argenx following positive topline Phase 3 data for Vyvgart in seronegative myasthenia gravis and successful primary endpoint achievement across patient subtypes, which expands the addressable market.Actualización de narrativa • Aug 29
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
argenx’s price target has been raised to €705.90 as analysts cite strong Vyvgart Phase 3 results, raised U.S. sales expectations, visible pipeline catalysts, and resilient uptake despite recent safety concerns. Analyst Commentary Bullish analysts cite Vyvgart’s positive Phase 3 ADAPT SERON results in seronegative generalized myasthenia gravis (gMG), demonstrating clinical improvement and supporting expansion into new patient subtypes.Actualización de narrativa • Aug 06
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
A sharp decline in argenx’s future P/E ratio, despite slightly lower revenue growth forecasts, has contributed to a notable increase in the consensus analyst price target from €665.23 to €700.31. What's in the News Argenx and Unnatural Products Inc.Artículo de análisis • Aug 01
What argenx SE's (EBR:ARGX) 25% Share Price Gain Is Not Telling You
argenx SE ( EBR:ARGX ) shares have had a really impressive month, gaining 25% after a shaky period beforehand. Looking...Artículo de análisis • Jun 30
We Think argenx (EBR:ARGX) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Nueva narrativa • Apr 27
Prefilled Syringe Launch And Pipeline Trials Will Expand Global Reach
Strong pipeline potential from advanced Phase III and proof-of-concept studies could drive new product approvals and market expansion, boosting revenues.Rentabilidad de los accionistas
| ARGX | BE Biotechs | Mercado BE | |
|---|---|---|---|
| 7D | 0.5% | 1.0% | 0.8% |
| 1Y | 32.3% | 28.9% | 19.6% |
Rentabilidad vs. Industria: ARGX superó a la industria Belgian Biotechs, que obtuvo un rendimiento del 28.9% el año pasado.
Rentabilidad vs. Mercado: ARGX superó al mercado Belgian, que obtuvo un rendimiento del 19.6% el año pasado.
Volatilidad de los precios
| ARGX volatility | |
|---|---|
| ARGX Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in BE Market | 6.8% |
| 10% least volatile stocks in BE Market | 2.7% |
Precio estable de las acciones: ARGX no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Belgian.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ARGX (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2008 | 1,863 | Karen Massey | argenx.com |
argenx SE, empresa biofarmacéutica en fase comercial, desarrolla diversas terapias para el tratamiento de enfermedades autoinmunes en Estados Unidos, Japón, China, Países Bajos e internacionalmente. La empresa ofrece VYGART y VYGART HYTRULO para tratar la miastenia grave generalizada (GMG), la trombocitopenia inmunitaria (PTI) y la polineuropatía desmielinizante inflamatoria crónica (PDIC). También desarrolla efgartigimod para el tratamiento de la gMG seronegativa y ocular, las enfermedades oculares tiroideas, la PTI, la miositis, la enfermedad de Sjögren, la nefropatía lúpica, la esclerosis sistémica, el rechazo mediado por anticuerpos y la encefalitis autoinmune; empasiprubart contra la neuropatía motora multifocal, la PDIC, el retraso de la función del injerto y la dermatomiositis; y ARGX-119 contra el síndrome miasténico congénito, la esclerosis lateral amiotrófica y la atrofia muscular espinal.
Resumen de fundamentos de argenx SE
| Estadísticas fundamentales de ARGX | |
|---|---|
| Capitalización bursátil | €42.93b |
| Beneficios(TTM) | €1.28b |
| Ingresos (TTM) | €4.08b |
33.5x
Ratio precio-beneficio (PE)10.5x
Ratio precio-ventas (PS)¿Está ARGX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ARGX | |
|---|---|
| Ingresos | US$4.74b |
| Coste de los ingresos | US$1.99b |
| Beneficio bruto | US$2.76b |
| Otros gastos | US$1.27b |
| Beneficios | US$1.49b |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Jul 23, 2026
| Beneficios por acción (BPA) | 23.94 |
| Margen bruto | 58.11% |
| Margen de beneficio neto | 31.40% |
| Ratio deuda/patrimonio | 0.6% |
¿Cómo se ha desempeñado ARGX a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 06:50 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
argenx SE está cubierta por 55 analistas. 30 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | Baird |
| Colleen Kusy | Baird |
| Joel Beatty | Baird |